C
6919
vs
T
Taiwan Weighted Index
Over the past 12 months, Caliway Biopharmaceuticals Co Ltd has underperformed Taiwan Weighted Index, delivering a return of +17% compared to the Taiwan Weighted Index's +52% growth.
Stocks Performance
6919 vs Taiwan Weighted Index
Performance Gap
6919 vs Taiwan Weighted Index
Performance By Year
6919 vs Taiwan Weighted Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Caliway Biopharmaceuticals Co Ltd
Glance View
Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.
